Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PROKR2 | Q8NFJ6 | 5/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL565319 | 0.93 | PROKR2 (0.68) | PROKR2KDM4EKMT2AMEN1MCHR1 | |
| SCHEMBL10106694 | 0.92 | PROKR2 (0.67) | PROKR2KDM4EKMT2AMEN1POLB | |
| SCHEMBL565417 | 0.92 | PROKR2 (0.67) | PROKR2KDM4EKMT2AMEN1POLB | |
| SCHEMBL10106779 | 0.91 | PROKR2 (0.70) | PROKR2KDM4EKMT2AMEN1POLB | |
| SCHEMBL10106784 | 0.91 | PROKR2 (0.70) | PROKR2KDM4EKMT2AMEN1MCHR1 | |
| SCHEMBL20936225 | 0.91 | PROKR2 (0.66) | PROKR2KDM4EKMT2AMEN1POLB | |
| SCHEMBL20915073 | 0.91 | PROKR2 (0.66) | PROKR2KDM4EKMT2AMEN1POLB | |
| SCHEMBL564942 | 0.91 | PROKR2 (0.69) | PROKR2KDM4EKMT2AMEN1POLB | |
| SCHEMBL565255 | 0.91 | PROKR2 (0.69) | PROKR2KDM4EKMT2AMCHR1POLB | |
| SCHEMBL565136 | 0.90 | PROKR2 (0.73) | PROKR2KDM4EKMT2AMEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722896-B2 | Prokineticin receptor antagonists and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-05-13 | — | — | US | disclosed |
| US-8722896-B2 | Prokineticin receptor antagonists and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-05-13 | — | — | US | disclosed |
| US-20120035149-A1 | Prokineticin Receptor Antagonists And Uses Thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-02-09 | — | — | US | disclosed |
| US-20120035149-A1 | Prokineticin Receptor Antagonists And Uses Thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035149-A1 | Prokineticin Receptor Antagonists And Uses Thereof | PROKR2, PROKR1, GIPR | PROKR2 1/4885KDM4E 4874/4885KMT2A 4644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.